We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-6.61%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$266M
AUM Growth
-$131K
Cap. Flow
+$22.7M
Cap. Flow %
8.53%
Top 10 Hldgs %
48.53%
Holding
95
New
9
Increased
25
Reduced
15
Closed
6

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$7.86M
2
APLS
Apellis Pharmaceuticals
APLS
+$4.67M
3
TVRD
Tvardi Therapeutics
TVRD
+$4.02M
4
ALEC icon
Alector
ALEC
+$2.2M
5
MGNX icon
MacroGenics
MGNX
+$2.16M

Top Sells

Rank Stock Value
1
QNCX icon
Quince Therapeutics
QNCX
+$2.78M
2
INDP icon
Indaptus Therapeutics
INDP
+$1.8M
3
NXTC icon
NextCure
NXTC
+$1.44M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$1.41M
5
ARGX icon
argenx
ARGX
+$1.32M

Sector Composition

Rank Sector Weight
1 Healthcare 92.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCYX icon
51
SCYNEXIS
SCYX
$48.1M
$1.36M 0.51%
15,912
– –
EPZM
52
DELISTED
Epizyme, Inc
EPZM
$1.26M 0.47%
121,986
-51,550
-30% -$650K
AUTL
53
Autolus Therapeutics
AUTL
$397M
$1.24M 0.47%
100,000
– –
JNJ icon
54
Johnson & Johnson
JNJ
$618B
$1.22M 0.46%
9,400
– –
GMDA
55
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$1.18M 0.44%
272,909
-2,091
-0.8% -$8.51K
INGN icon
56
Inogen
INGN
$175M
$1.1M 0.41%
23,000
– –
SYBX
57
DELISTED
Synlogic
SYBX
$991K 0.37%
+28,855
New +$2.09M
FOMX
58
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$929K 0.35%
305,500
-502,500
-62% -$1.41M
PRVL
59
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$921K 0.35%
75,000
– –
BTAI icon
60
BioXcel Therapeutics
BTAI
$24.9M
$898K 0.34%
+7,969
New +$1.26M
STIM icon
61
Neuronetics
STIM
$138M
$883K 0.33%
+106,247
New +$1.16M
MRSN
62
DELISTED
Mersana Therapeutics
MRSN
$793K 0.3%
20,069
+9,060
+82% +$659K
CTMX icon
63
CytomX Therapeutics
CTMX
$675M
$738K 0.28%
+100,000
New +$986K
DERM
64
DELISTED
Dermira, Inc.
DERM
$665K 0.25%
104,000
– –
VIRX
65
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$663K 0.25%
+26,314
New +$759K
MDGL icon
66
Madrigal Pharmaceuticals
MDGL
$10.8B
$569K 0.21%
6,600
– –
RDUS
67
DELISTED
Radius Health, Inc.
RDUS
$567K 0.21%
22,000
– –
OBSV
68
DELISTED
ObsEva SA Ordinary Shares
OBSV
$535K 0.2%
64,231
+14,383
+29% +$137K
INSM icon
69
Insmed
INSM
$21.4B
$529K 0.2%
30,000
– –
ASMB icon
70
Assembly Biosciences
ASMB
$498M
$497K 0.19%
4,214
– –
MASI
71
DELISTED
Masimo
MASI
$446K 0.17%
3,000
– –
GRTS
72
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$432K 0.16%
50,000
– –
SPRO icon
73
Spero Therapeutics
SPRO
$67.7M
$418K 0.16%
39,395
-30,605
-44% -$323K
STRO icon
74
Sutro Biopharma
STRO
$401M
$364K 0.14%
4,000
+851
+27% +$85.9K
URGN icon
75
UroGen Pharma
URGN
$1.86B
$357K 0.13%
15,000
– –
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, DAFNA Capital Management held 95 positions worth $266M, down 0.05% from $266M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management deployed $22.7M of net new capital in Q3 2019, opening 9 new positions and adding to 25 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 169,800 shares worth $4.09M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was Foamix Pharmaceuticals Ltd. Ordinary Shares, an estimated $1.41M trimmed.

  • DAFNA Capital Management's largest Q3 2019 buy was Apellis Pharmaceuticals: 169,800 shares worth $4.09M.
  • DAFNA Capital Management added most to Fate Therapeutics in Q3 2019, an estimated $7.86M increase.
  • DAFNA Capital Management's biggest Q3 2019 reduction was Foamix Pharmaceuticals Ltd. Ordinary Shares, cutting an estimated $1.41M.
  • DAFNA Capital Management fully exited Quince Therapeutics in Q3 2019, selling an estimated $2.78M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $266M portfolio in Q3 2019.
  • DAFNA Capital Management opened 9 new positions and closed 6 in Q3 2019.
  • DAFNA Capital Management's portfolio value fell 0.05% quarter-over-quarter to $266M.

Based on DAFNA Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.